Figure S19 and references for supplementary figures from ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms

Factors associated with resistance to idelalisib in cell lines are expressed in clinical specimens. Expression levels of genes related to idelalisib resistance were studied across different subtypes of B cell lymphoma: (A) n=48 (5), (B) n=80 (6). B-CLL: chronic lymphocytic leukemia, B.FL: follicular lymphoma, LBNH: non-specified non-Hodgkin B cell lymphoma, MALT: MZL of the mucosa associated tissue, MCL: Mantle cell lymphoma, NMZL: nodal marginal zone lymphoma, SMZL: splenic marginal zone lymphoma. Expression levels of genes related to idelalisib resistance were studied across the subtypes of diffuse large B cell lymphoma (DLBCL, two series: (C) n=181 and (D) n=223 from GSE10846 (7). ABC: activated B cell like DLBCL, GCB: germinal center B cell like DLBCL, type3: type3 DLBCL. Red for highly expressed gene in B cells (CD79A), blue for not expressed gene in B cells (IGFBP1), black for the gene of interest. (E) Gene set enrichment analyses comparing resistant versus parental for the top-200 genes positively correlated genes with HBEGF in SMZL clinical specimens (6). NES: normalized enrichment score, p-val: nominal p-value, FDR: false discovery rate.